Tumor Growth Rate to Assess Tumor Activity in Patients with Lung Neuroendocrine Tumors on Lanreotide Autogel: A Case-Series Analysis

#1606

Introduction: The slow-growing character of neuroendocrine tumors (NET) makes it difficult to assess treatment impact on tumor growth.

Aim(s): Tumor growth rate (TGR) could be a new way to evaluate tumor dynamics in NET.

Materials and methods: This retrospective case-series analysis was performed on 3 patients in Belgium (ages 80 [P1, male], 78 [P2, male] and 69 years [P3, female]) with lung NET stabilized on lanreotide Autogel (LAN, 120 mg/month). Tumor lesions at LAN therapy start (baseline) and after 78 (P1), 46 (P2) and 38 months (P3) were identified by computed tomography (CT) and measured according to RECIST 1.0. TGR (% change in tumor volume/month) was calculated from the sum of the longest diameters (SLDs) of the target lesions before and after LAN therapy start. Analyses are descriptive.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Van Fraeyenhove F, Meireson N, Mattelaer C, De Droogh E, Galdermans D,

Keywords: non-functional lung neuroendocrine tumors, lanreotide, tumor growth, case-series,